TY - JOUR
T1 - Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization
AU - Nakagawa, Yasuko
AU - Numoto, Kunihiko
AU - Yoshida, Aki
AU - Kunisada, Toshiyuki
AU - Ohata, Hidenori
AU - Takeda, Ken
AU - Wai, Daniel
AU - Poremba, Christopher
AU - Ozaki, Toshifumi
N1 - Funding Information:
Acknowledgments Supported in part by a Grant-in-Aid for Clinical Cancer Research and Grant-in-Aid for Cancer Research (14S-4 and -5) from the Ministry of Health, Labor and Welfare, Japan; by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports, and Culture (No. 14370464); and by a Grant-in-Aid from Japan Orthopaedics and Traumatology Foundation, Inc. (J.O.T.F. Grant No. 0134).
PY - 2006/7
Y1 - 2006/7
N2 - Purpose: To analyze the relationship between chromosomal instabilities and clinicopathological factors in synovial sarcoma (SS). Methods: Twenty-two fresh-frozen SS were analyzed by metaphase comparative genomic hybridization (CGH). Additional microarray CGH was performed in 13 cases. Results: Fourteen patients with SYT-SSX1 rearrangements and nine patients with biphasic tumor subtypes had better prognosis than the eight patients with SYT-SSX2 rearrangements and 13 patients with monophasic subtypes, respectively. Gains (average 3.0) were more frequent than losses (average 1.0). Frequent gains were identified on chromosomal regions 2, 6q, 7, 8q, 12, 17q, 18q, and 21q, whereas frequent losses were over-lapped on chromosomes 1p31-p35, 3p, 6q, 16, and 17p. High-level gains were observed on chromosomes 1q21-q31, 7, 8, 12, 17q, 18q, and 21q. Thirteen monophasic and nine biphasic tumors had an average of 5.1 and 2.8 aberrations, respectively. Patients with tumors harboring numerous aberrations (≥3) had a worse clinical course. Microarray CGH more specifically detected genetic imbalances including gains in MDM2, MSH2, KCNK12, DCC, CDK2, ERBB3, SAS, and CDK4 and losses in HRAS, RASSF1, and CCND1. Gain of SAS was an important prognostic factor of SS. Conclusion: We have identified several factors influencing the prognosis of SS patients by metaphase and microarray CGH.
AB - Purpose: To analyze the relationship between chromosomal instabilities and clinicopathological factors in synovial sarcoma (SS). Methods: Twenty-two fresh-frozen SS were analyzed by metaphase comparative genomic hybridization (CGH). Additional microarray CGH was performed in 13 cases. Results: Fourteen patients with SYT-SSX1 rearrangements and nine patients with biphasic tumor subtypes had better prognosis than the eight patients with SYT-SSX2 rearrangements and 13 patients with monophasic subtypes, respectively. Gains (average 3.0) were more frequent than losses (average 1.0). Frequent gains were identified on chromosomal regions 2, 6q, 7, 8q, 12, 17q, 18q, and 21q, whereas frequent losses were over-lapped on chromosomes 1p31-p35, 3p, 6q, 16, and 17p. High-level gains were observed on chromosomes 1q21-q31, 7, 8, 12, 17q, 18q, and 21q. Thirteen monophasic and nine biphasic tumors had an average of 5.1 and 2.8 aberrations, respectively. Patients with tumors harboring numerous aberrations (≥3) had a worse clinical course. Microarray CGH more specifically detected genetic imbalances including gains in MDM2, MSH2, KCNK12, DCC, CDK2, ERBB3, SAS, and CDK4 and losses in HRAS, RASSF1, and CCND1. Gain of SAS was an important prognostic factor of SS. Conclusion: We have identified several factors influencing the prognosis of SS patients by metaphase and microarray CGH.
KW - Chromosome
KW - Comparative genomic hybridization
KW - Instability
KW - Microarray
KW - Synovial sarcoma
UR - http://www.scopus.com/inward/record.url?scp=33646746854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646746854&partnerID=8YFLogxK
U2 - 10.1007/s00432-006-0089-5
DO - 10.1007/s00432-006-0089-5
M3 - Article
C2 - 16557383
AN - SCOPUS:33646746854
SN - 0171-5216
VL - 132
SP - 444
EP - 450
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 7
ER -
